Catalogo dei prodotti della ricerca

This review summarizes the current state of knowledge on non-alcoholic fatty liver disease (NAFLD) and the hepatitis C virus (HCV)-associated liver fibrosis, and provides insight into the role of dysmetabolism in hepatic fibrogenesis. Clinical relevance of drugs correcting these metabolic disturbances in the reversion of liver fibrosis will also be discussed.

Liver fibrosis and therapeutic strategies: the goal for improving metabolism / Nobili, V.. - In: CURRENT DRUG TARGETS. - ISSN 1873-5592. - 10:6(2009), p. 505-12.

Liver fibrosis and therapeutic strategies: the goal for improving metabolism

Nobili V.
2009

Abstract

This review summarizes the current state of knowledge on non-alcoholic fatty liver disease (NAFLD) and the hepatitis C virus (HCV)-associated liver fibrosis, and provides insight into the role of dysmetabolism in hepatic fibrogenesis. Clinical relevance of drugs correcting these metabolic disturbances in the reversion of liver fibrosis will also be discussed.
2009
Animals; Fatty Liver; Hepatitis C; Humans; Liver Cirrhosis; Models, Biological; Risk Factors
01 Pubblicazione su rivista::01a Articolo in rivista
Liver fibrosis and therapeutic strategies: the goal for improving metabolism / Nobili, V.. - In: CURRENT DRUG TARGETS. - ISSN 1873-5592. - 10:6(2009), p. 505-12.
01a Articolo in rivista
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1177925
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact